Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Consolidation of Variable Interest Entity - Pro Forma Financial Information (Details)

v3.5.0.2
Note 3 - Consolidation of Variable Interest Entity - Pro Forma Financial Information (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Milestone Medical Inc. & Milestone Education LLC [Member] | Pro Forma [Member] | Milestone China [Member]        
Income (loss) in equity investments   $ (123,083)   $ (187,063)
Income (Loss) from Equity Method Investments   (123,083)   (187,063)
Milestone Medical Inc. & Milestone Education LLC [Member] | Pro Forma [Member]        
Total revenue   2,509,096   7,099,164
Cost of Goods Sold   805,429   2,312,980
Gross Profit   1,703,667   4,786,184
Selling, general and administrative expenses   3,481,703   9,609,318
Research and development expenses   217,138   621,870
Operating expenses   3,698,841   10,231,188
Loss from operations   (1,995,174)   (5,445,004)
Interest expense   (18,237)   (21,655)
Loss before provision for income tax and equity in net earnings of equity investments   (2,013,411)   (5,466,659)
Provision for Income Tax   (27,105)   (40,751)
Loss before equity in net earnings of equity investments   (2,040,516)   (5,507,410)
Income (loss) in equity investments   (123,083)   (187,063)
Income (Loss) from Equity Method Investments   (123,083)   (187,063)
Net loss   (2,163,599)   (5,694,473)
Less: Net loss attributable to the noncontrolling interests   594,397   1,632,948
Net loss attributable to Milestone Scientific Inc.   (1,569,202)   (4,061,525)
Milestone China [Member]        
Income (loss) in equity investments $ (253,451) (123,083) $ (554,766) (187,062)
Income (Loss) from Equity Method Investments (253,451) (123,083) (554,766) (187,062)
Total revenue 3,186,596 2,459,958 8,973,726 6,996,921
Cost of Goods Sold 1,517,561 794,285 3,675,552 2,298,162
Gross Profit 1,669,035 1,665,673 5,298,174 4,698,759
Selling, general and administrative expenses 2,933,950 2,480,354 9,226,062 6,969,332
Research and development expenses 303,268 20,676 756,045 49,616
Operating expenses 3,237,218 2,501,030 9,982,107 7,018,948
Loss from operations (1,568,183) (835,357) (4,683,933) (2,320,189)
Interest expense (846) (1,043) (2,782) (961)
Loss before provision for income tax and equity in net earnings of equity investments (1,569,029) (836,400) (4,686,715) (2,321,150)
Provision for Income Tax 16,522 27,105 80,147 40,751
Loss before equity in net earnings of equity investments (1,585,551) (863,505) (4,766,862) (2,361,901)
Income (loss) in equity investments (253,451) (711,352) (554,766) (1,759,266)
Income (Loss) from Equity Method Investments (253,451) (711,352) (554,766) (1,759,266)
Net loss (1,839,002) (1,574,857) (5,321,628) (4,121,167)
Less: Net loss attributable to the noncontrolling interests 137,752 5,655 1,113,958 59,642
Net loss attributable to Milestone Scientific Inc. $ (1,701,250) $ (1,569,202) $ (4,207,670) $ (4,061,525)